NCT05961410View on ClinicalTrials.gov

Eltrombopag for Peripheral Blood Stem Cell Harvest

PHASE2RecruitingINTERVENTIONAL

Enrollment

46

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

March 1, 2026

Conditions

LymphomaPeripheral Blood Stem Cell Transplantation

Interventions

DRUG

Eltrombopag olamine

Patients will receive eltrombopag 75 mg/day from ESHAP D6 until end of stem cell harvest.

Trial Locations (1)

Unknown

RECRUITING

National Taiwan University Hospital, Taipei

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

National Taiwan University Hospital

OTHER